Cybin Gestione

Criteri Gestione verificati 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Mike Cola

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	4.8yrs
Durata media del Consiglio di amministrazione	5.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Feb 25

AMMINISTRATORE DELEGATO

Mike Cola (65 yo)

less than a year

Mandato

Mr. Michael F. Cola, also known as Mike, is Chief Executive Officer of Cybin Inc. from February 10, 2026. Mr. Cola is an Independent Chairman of Phathom Pharmaceuticals, Inc. He served as Chief Executive O...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Eric So	Co-Founder	5.3yrs	US$6.84m	0.62% $ 2.3m
Paul Glavine	Co-Founder	no data	US$6.84m	0.56% $ 2.1m
Greg Cavers	Chief Financial Officer	5.3yrs	US$1.00m	0.038% $ 139.6k
Gabriel Fahel	Chief Legal Officer & Corporate Secretary	5.3yrs	US$1.12m	0.077% $ 282.6k
George Tziras	Chief Business Officer	2.4yrs	US$843.49k	0.072% $ 266.6k
Michael Cola	Chief Executive Officer	less than a year	Nessun dato	Nessun dato
John Kanakis	Co-Founder	no data	US$1.19m	Nessun dato
Aaron Bartlone	Chief Operating Officer	2.7yrs	US$764.06k	0.069% $ 252.2k
Alex Nivorozhkin	Chief Scientific Officer	5.3yrs	Nessun dato	Nessun dato
Lori Challenger	Chief Compliance	4.4yrs	Nessun dato	Nessun dato
Sara Somerset	Chief Communications Officers	no data	Nessun dato	Nessun dato
Douglas Sommerville	Chief Pharmaceutical Strategist	no data	Nessun dato	Nessun dato

4.8yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di HELP è considerato esperto (durata media dell'incarico 4.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Eric So	Co-Founder	5.3yrs	US$6.84m	0.62% $ 2.3m
Paul Glavine	Co-Founder	5.3yrs	US$6.84m	0.56% $ 2.1m
Theresa Firestone	Lead Independent Director	4.6yrs	US$286.56k	0.052% $ 191.5k
Mark Lawson	Independent Director	5.3yrs	US$291.77k	0.056% $ 206.0k
Grant Froese	Independent Director	5.3yrs	US$271.58k	0.060% $ 222.4k
Eric Hoskins	Independent Director	5.3yrs	US$271.58k	0.055% $ 203.1k

5.3yrs

Durata media

57.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HELP sono considerati esperti (durata media dell'incarico 5.3 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/03/01 04:50
Prezzo dell'azione a fine giornata	2026/02/27 00:00
Utili	2025/12/31
Utili annuali	2025/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub, abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Cybin Inc. è coperta da 13 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
James Molloy	Alliance Global Partners
David Martin	Bloom Burton & Co.
Sumant Satchidanand Kulkarni	Canaccord Genuity

Cybin Gestione

Criteri Gestione verificati 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee

Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026

Insider recently bought US$73k worth of stock

Cybin Inc. Announces Chief Executive Officer Changes

Cybin Inc. Announces George Tziras Not Standing for Re-Election

Cybin Inc., Annual General Meeting, Aug 18, 2025

Recent updates

Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2A Trial of Spl026 in Major Depressive Disorder

Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Inc. to Report Q2, 2026 Results on Nov 13, 2025

Cybin Inc. has completed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. Highlights Upcoming Clinical Milestones

Cybin Inc. Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Insider recently bought US$73k worth of stock

Cybin Inc. Announces Chief Executive Officer Changes

Cybin Inc. Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Announces George Tziras Not Standing for Re-Election

New major risk - Financial position

Cybin Inc. Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

New minor risk - Shareholder dilution

No longer forecast to breakeven

Cybin Inc. announced that it expects to receive $500 million in funding from High Trail Special Situations LLC

Cybin Inc., Annual General Meeting, Aug 18, 2025

Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

New minor risk - Share price stability

Cybin Inc. Announces Additional U.S. Patent Supporting Its Cyb003 Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

No longer forecast to breakeven

New minor risk - Share price stability

Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin Inc. Announces Executive Appointments

Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones

Insufficient new directors

Forecast to breakeven in 2027

Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee

Cybin Inc., Annual General Meeting, Aug 27, 2024

Co-Founder recently bought US$64k worth of stock

No longer forecast to breakeven

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Forecast to breakeven in 2027

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin Inc. has completed a Composite Units Offering in the amount of $30 million.

New major risk - Revenue and earnings growth

Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

Cybin Inc. Announces that George Tziras Joins the Board of Directors and Will Serve as Chief Business Officer

New major risk - Shareholder dilution

Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

Cybin Inc. agreed to acquire Small Pharma Inc. (TSXV : DMT) for $23.2 million.

Cybin Inc. Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial

New major risk - Financial position

Cybin Inc. has completed a Composite Units Offering in the amount of $8.25 million.

Cybin Inc. Announces Phase 2 Cohort 5 Dosing Completion of Cyb003 in Major Depressive Disorder

Cybin Inc. Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin Inc. Announces the Development of Scalable Psychedelic Facilitation Training Program, Embarkct

New minor risk - Share price stability

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023

Cybin Inc., Annual General Meeting, Aug 29, 2023